Monday, May 22, 2023

#TheBigCatchUp: Takeda Healthcare Philippines joined WHO for World Immunization Week 2023; shared key updates on dengue vaccine

 

Takeda Healthcare Philippines Inc. (“Takeda Philippines”) joined the World Health Organization (WHO) for World Immunization Week 2023 heeding the latter's call for protecting millions of people around the world from vaccine-preventable diseases.

 

Takeda Philippines is proud to support WHO’s World Immunization Week for the second year in a row, with this year’s theme, #TheBigCatchUp. Working with partners and volunteers all around the world, WHO wants to ensure that people, especially children, are on track with their vaccinations, to restore essential immunization coverage to 2019 levels, and to strengthen vaccine deliveries through primary healthcare. World Immunization Week is a yearly campaign by the WHO aiming to bring awareness and reflect on the essential role vaccinations play in promoting global health.

 

“Immunizations are an essential asset for global public health and a basic health care right to help protect families and communities against infectious disease,” Shun Mori, Head of the Established Vaccine Program and Japan Business Coordinator, spoke about the importance of WHO’s World Immunization Week campaign.

 

“Takeda has supplied vaccines against burdensome diseases for the individuals of Japan, and we take pride in furthering this effort to continue bettering the health of people all around the world.” he added.

 

Unwavering Commitment to Vaccine Innovation & Vaccine for All

Takeda has dedicated more than 70 years in developing and providing vaccines in Japan, facing the most difficult problems in public health by developing innovative vaccines to prevent the spread of new diseases. Today, they have taken the challenge of introducing a new vaccine for one of the most challenging infectious diseases known to mankind, Dengue.

 

Takeda has recently developed a dengue vaccine aimed to curb the deadly dengue disease regardless of previous exposure. Dengue is a mosquito-borne viral disease common in many tropical countries such as the Philippines, and is listed by the WHO as one of the ten threats to global health. The vaccine is currently approved for use in Brazil, Indonesia and Thailand where dengue is endemic[1]. The vaccine is also approved for use in the European Union. 

 

A child with a bandage on his arm

Description automatically generated with low confidence

Takeda has developed a new vaccine for the deadly Dengue virus, which has now been approved for use in Brazil, Indonesia, Thailand and the European Union.

 

“We look forward to bringing Takeda’s dengue vaccine to the Philippines in the near future. We will work with the government and private sectors to address the burden of the dengue disease which has long remained endemic for decades and is responsible for over 200,000 cases in 2022 alone,” shared Loreann Villanueva, Country Manager of Takeda Healthcare Philippines. 

 

Takeda Healthcare Philippines is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, a global R&D-driven biopharmaceutical company.

# # #

About Takeda

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.

Takeda Healthcare Philippines, Inc. (THPI) is a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited. Founded in 1968, THPI aims to broaden patient access to treatment across the country through sustainable access programs enabling affordable and integrated access solutions for disease areas such as oncology, gastroenterology, rare diseases & vaccines and by strengthening the healthcare system guided by our commitment to Patients, our People and the Planet.

For more information, visit https://www.takeda.com.

 

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

 

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

 

Medical information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

 

 

 



[1] Center for Disease Control. Dengue Around the World. Retrieved May 2023.

Takeda Healthcare Philippines Inc. (“Takeda Philippines”) joined the World Health Organization (WHO) for World Immunization Week 2023 heeding the latter's call for protecting millions of people around the world from vaccine-preventable diseases.

 

Takeda Philippines is proud to support WHO’s World Immunization Week for the second year in a row, with this year’s theme, #TheBigCatchUp. Working with partners and volunteers all around the world, WHO wants to ensure that people, especially children, are on track with their vaccinations, to restore essential immunization coverage to 2019 levels, and to strengthen vaccine deliveries through primary healthcare. World Immunization Week is a yearly campaign by the WHO aiming to bring awareness and reflect on the essential role vaccinations play in promoting global health.

 

“Immunizations are an essential asset for global public health and a basic health care right to help protect families and communities against infectious disease,” Shun Mori, Head of the Established Vaccine Program and Japan Business Coordinator, spoke about the importance of WHO’s World Immunization Week campaign.

 

“Takeda has supplied vaccines against burdensome diseases for the individuals of Japan, and we take pride in furthering this effort to continue bettering the health of people all around the world.” he added.

 

Unwavering Commitment to Vaccine Innovation & Vaccine for All

Takeda has dedicated more than 70 years in developing and providing vaccines in Japan, facing the most difficult problems in public health by developing innovative vaccines to prevent the spread of new diseases. Today, they have taken the challenge of introducing a new vaccine for one of the most challenging infectious diseases known to mankind, Dengue.

 

Takeda has recently developed a dengue vaccine aimed to curb the deadly dengue disease regardless of previous exposure. Dengue is a mosquito-borne viral disease common in many tropical countries such as the Philippines, and is listed by the WHO as one of the ten threats to global health. The vaccine is currently approved for use in Brazil, Indonesia and Thailand where dengue is endemic[1]. The vaccine is also approved for use in the European Union. 

 



TTakeda Healthcare Philippines Inc. (“Takeda Philippines”) joined the World Health Organization (WHO) for World Immunization Week 2023 heeding the latter's call for protecting millions of people around the world from vaccine-preventable diseases.

 

Takeda Philippines is proud to support WHO’s World Immunization Week for the second year in a row, with this year’s theme, #TheBigCatchUp. Working with partners and volunteers all around the world, WHO wants to ensure that people, especially children, are on track with their vaccinations, to restore essential immunization coverage to 2019 levels, and to strengthen vaccine deliveries through primary healthcare. World Immunization Week is a yearly campaign by the WHO aiming to bring awareness and reflect on the essential role vaccinations play in promoting global health.

 

“Immunizations are an essential asset for global public health and a basic health care right to help protect families and communities against infectious disease,” Shun Mori, Head of the Established Vaccine Program and Japan Business Coordinator, spoke about the importance of WHO’s World Immunization Week campaign.

 

“Takeda has supplied vaccines against burdensome diseases for the individuals of Japan, and we take pride in furthering this effort to continue bettering the health of people all around the world.” he added.

 

Unwavering Commitment to Vaccine Innovation & Vaccine for All

Takeda has dedicated more than 70 years in developing and providing vaccines in Japan, facing the most difficult problems in public health by developing innovative vaccines to prevent the spread of new diseases. Today, they have taken the challenge of introducing a new vaccine for one of the most challenging infectious diseases known to mankind, Dengue.

 

Takeda has recently developed a dengue vaccine aimed to curb the deadly dengue disease regardless of previous exposure. Dengue is a mosquito-borne viral disease common in many tropical countries such as the Philippines, and is listed by the WHO as one of the ten threats to global health. The vaccine is currently approved for use in Brazil, Indonesia and Thailand where dengue is endemic[1]. The vaccine is also approved for use in the European Union. 

 


Takeda has developed a new vaccine for the deadly Dengue virus, which has now been approved for use in Brazil, Indonesia, Thailand and the European Union.

 

“We look forward to bringing Takeda’s dengue vaccine to the Philippines in the near future. We will work with the government and private sectors to address the burden of the dengue disease which has long remained endemic for decades and is responsible for over 200,000 cases in 2022 alone,” shared Loreann Villanueva, Country Manager of Takeda Healthcare Philippines. 

 

Takeda Healthcare Philippines is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, a global R&D-driven biopharmaceutical company.

# # #

About Takeda

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.

Takeda Healthcare Philippines, Inc. (THPI) is a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited. Founded in 1968, THPI aims to broaden patient access to treatment across the country through sustainable access programs enabling affordable and integrated access solutions for disease areas such as oncology, gastroenterology, rare diseases & vaccines and by strengthening the healthcare system guided by our commitment to Patients, our People and the Planet.

For more information, visit https://www.takeda.com.

 

 

 

Media Contacts:

Takeda Philippines

Arabella Benito - arabella.benito@takeda.com

 

COMCO Southeast Asia

Ferdinand Bondoy - ferdinand.bondoy@comcosea.com

Joyce Yu - joyce.yu@comcosea.com

Pinky Tuason – pinky.tuason@comcosea.com   

 

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

 

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”,

 

“hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

 

Medical information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

 

 

 



[1] Center for Disease Control. Dengue Around the World. Retrieved May 2023.

“We look forward to bringing Takeda’s dengue vaccine to the Philippines in the near future. We will work with the government and private sectors to address the burden of the dengue disease which has long remained endemic for decades and is responsible for over 200,000 cases in 2022 alone,” shared Loreann Villanueva, Country Manager of Takeda Healthcare Philippines. 

 

Takeda Healthcare Philippines is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, a global R&D-driven biopharmaceutical company.


About Takeda

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.

Takeda Healthcare Philippines, Inc. (THPI) is a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited. Founded in 1968, THPI aims to broaden patient access to treatment across the country through sustainable access programs enabling affordable and integrated access solutions for disease areas such as oncology, gastroenterology, rare diseases & vaccines and by strengthening the healthcare system guided by our commitment to Patients, our People and the Planet.

For more information, visit https://www.takeda.com.

 

 

 

Media Contacts:

Takeda Philippines

Arabella Benito - arabella.benito@takeda.com

 

COMCO Southeast Asia

Ferdinand Bondoy - ferdinand.bondoy@comcosea.com

Joyce Yu - joyce.yu@comcosea.com

Pinky Tuason – pinky.tuason@comcosea.com   

 

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

 

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

 

Medical information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

 

 

 



No comments:

One Filipino per Hour Develops Chronic Renal Failure

Chronic Kidney Disease or CKD is one of the leading causes of death in the Philippines [1] . According to the National Kidney Transplant I...